| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 385 | 2024 | 8863 | 22.440 |
Why?
|
| Glioblastoma | 212 | 2024 | 3481 | 17.840 |
Why?
|
| Glioma | 172 | 2024 | 3401 | 17.270 |
Why?
|
| Angiogenesis Inhibitors | 62 | 2023 | 2038 | 7.570 |
Why?
|
| Neoplasm Recurrence, Local | 114 | 2023 | 9239 | 5.770 |
Why?
|
| Meningeal Neoplasms | 45 | 2023 | 1241 | 5.590 |
Why?
|
| Central Nervous System Neoplasms | 32 | 2024 | 895 | 5.180 |
Why?
|
| Dacarbazine | 42 | 2022 | 566 | 5.060 |
Why?
|
| Meningioma | 34 | 2022 | 1209 | 4.960 |
Why?
|
| Antineoplastic Agents | 116 | 2023 | 13695 | 4.490 |
Why?
|
| Antineoplastic Agents, Alkylating | 26 | 2022 | 627 | 3.800 |
Why?
|
| Clinical Trials as Topic | 55 | 2023 | 7913 | 2.870 |
Why?
|
| Isocitrate Dehydrogenase | 24 | 2023 | 871 | 2.630 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 61 | 2023 | 11524 | 2.510 |
Why?
|
| Cranial Irradiation | 11 | 2020 | 401 | 2.160 |
Why?
|
| Brain Edema | 9 | 2021 | 617 | 2.070 |
Why?
|
| Nervous System Neoplasms | 5 | 2015 | 91 | 1.970 |
Why?
|
| Pyridines | 16 | 2023 | 2825 | 1.920 |
Why?
|
| Quinazolines | 28 | 2017 | 1356 | 1.890 |
Why?
|
| Oligodendroglioma | 13 | 2023 | 279 | 1.880 |
Why?
|
| Astrocytoma | 19 | 2023 | 790 | 1.840 |
Why?
|
| Humans | 597 | 2024 | 744343 | 1.770 |
Why?
|
| Disease-Free Survival | 57 | 2021 | 6895 | 1.560 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 16 | 2017 | 664 | 1.540 |
Why?
|
| Vascular Endothelial Growth Factor A | 20 | 2023 | 3508 | 1.500 |
Why?
|
| Pyrimidines | 13 | 2022 | 2942 | 1.500 |
Why?
|
| Endpoint Determination | 12 | 2020 | 601 | 1.480 |
Why?
|
| Disease Progression | 49 | 2023 | 13284 | 1.420 |
Why?
|
| Neurology | 7 | 2024 | 763 | 1.370 |
Why?
|
| Somatostatin | 3 | 2015 | 459 | 1.350 |
Why?
|
| Imidazoles | 10 | 2023 | 1206 | 1.320 |
Why?
|
| Protein Kinase Inhibitors | 21 | 2023 | 5535 | 1.310 |
Why?
|
| Adult | 229 | 2024 | 214055 | 1.280 |
Why?
|
| Combined Modality Therapy | 41 | 2023 | 8642 | 1.280 |
Why?
|
| Oxazines | 2 | 2020 | 298 | 1.280 |
Why?
|
| Anilides | 5 | 2018 | 408 | 1.270 |
Why?
|
| Lomustine | 9 | 2023 | 59 | 1.250 |
Why?
|
| Treatment Outcome | 122 | 2023 | 63114 | 1.210 |
Why?
|
| Adrenal Cortex Hormones | 9 | 2019 | 1855 | 1.150 |
Why?
|
| Molecular Targeted Therapy | 16 | 2023 | 2727 | 1.140 |
Why?
|
| Aged | 183 | 2023 | 163280 | 1.110 |
Why?
|
| Salvage Therapy | 12 | 2018 | 1275 | 1.100 |
Why?
|
| Magnetic Resonance Imaging | 72 | 2024 | 35421 | 1.090 |
Why?
|
| Medical Oncology | 13 | 2024 | 2265 | 1.090 |
Why?
|
| Anticonvulsants | 23 | 2024 | 1916 | 1.080 |
Why?
|
| Middle Aged | 208 | 2023 | 213383 | 1.070 |
Why?
|
| Seizures | 13 | 2024 | 2859 | 1.060 |
Why?
|
| Neovascularization, Pathologic | 16 | 2018 | 2635 | 1.040 |
Why?
|
| Radiosurgery | 18 | 2023 | 1329 | 1.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 11 | 2020 | 629 | 1.030 |
Why?
|
| Mutation | 51 | 2024 | 29786 | 1.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2015 | 1524 | 0.980 |
Why?
|
| Enzyme Inhibitors | 11 | 2023 | 3798 | 0.970 |
Why?
|
| Head | 5 | 2010 | 880 | 0.940 |
Why?
|
| Models, Neurological | 5 | 2010 | 1774 | 0.940 |
Why?
|
| Male | 244 | 2023 | 350118 | 0.930 |
Why?
|
| Aminopyridines | 6 | 2020 | 542 | 0.930 |
Why?
|
| World Health Organization | 8 | 2022 | 1318 | 0.920 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2015 | 323 | 0.900 |
Why?
|
| Radiotherapy | 14 | 2017 | 1533 | 0.890 |
Why?
|
| Maximum Tolerated Dose | 18 | 2020 | 892 | 0.890 |
Why?
|
| Recombinant Fusion Proteins | 10 | 2020 | 3772 | 0.890 |
Why?
|
| Female | 232 | 2024 | 380194 | 0.870 |
Why?
|
| Proto-Oncogene Proteins B-raf | 10 | 2023 | 2043 | 0.860 |
Why?
|
| Prognosis | 68 | 2023 | 29063 | 0.850 |
Why?
|
| DNA Repair Enzymes | 12 | 2023 | 349 | 0.850 |
Why?
|
| DNA Modification Methylases | 11 | 2023 | 206 | 0.850 |
Why?
|
| Problem Solving | 2 | 2015 | 440 | 0.840 |
Why?
|
| Tumor Burden | 14 | 2023 | 1915 | 0.840 |
Why?
|
| Gliosarcoma | 11 | 2022 | 114 | 0.830 |
Why?
|
| Antibodies, Monoclonal | 21 | 2022 | 9274 | 0.830 |
Why?
|
| Survival Rate | 50 | 2021 | 12788 | 0.820 |
Why?
|
| Hydroxamic Acids | 3 | 2015 | 494 | 0.820 |
Why?
|
| Central Nervous System | 6 | 2023 | 1357 | 0.810 |
Why?
|
| Patient Selection | 7 | 2020 | 4215 | 0.800 |
Why?
|
| Diamines | 1 | 2021 | 59 | 0.780 |
Why?
|
| Research Design | 19 | 2023 | 5987 | 0.780 |
Why?
|
| Pepsin A | 1 | 2021 | 71 | 0.770 |
Why?
|
| Indoles | 6 | 2015 | 1839 | 0.750 |
Why?
|
| Glycine | 3 | 2022 | 671 | 0.750 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2019 | 3479 | 0.750 |
Why?
|
| Morpholines | 4 | 2020 | 571 | 0.750 |
Why?
|
| Neoplasms | 22 | 2023 | 21683 | 0.740 |
Why?
|
| Lactoferrin | 1 | 2021 | 97 | 0.740 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2022 | 934 | 0.730 |
Why?
|
| Diagnostic Imaging | 12 | 2022 | 3507 | 0.730 |
Why?
|
| Fatigue | 6 | 2017 | 1531 | 0.730 |
Why?
|
| Phosphatidylinositol 3-Kinases | 9 | 2023 | 2938 | 0.710 |
Why?
|
| Cancer Vaccines | 6 | 2019 | 1023 | 0.700 |
Why?
|
| Editorial Policies | 2 | 2015 | 451 | 0.690 |
Why?
|
| Brain | 36 | 2022 | 26385 | 0.690 |
Why?
|
| Consensus | 11 | 2024 | 2959 | 0.690 |
Why?
|
| Phosphatidylinositol 3-Kinase | 2 | 2023 | 130 | 0.680 |
Why?
|
| Pharmaceutical Preparations | 4 | 2023 | 1071 | 0.680 |
Why?
|
| Blood-Brain Barrier | 6 | 2018 | 1017 | 0.670 |
Why?
|
| Peripheral Nervous System Diseases | 8 | 2018 | 685 | 0.660 |
Why?
|
| Positron-Emission Tomography | 10 | 2024 | 6234 | 0.660 |
Why?
|
| Radiation Injuries | 8 | 2020 | 1180 | 0.650 |
Why?
|
| Drug Resistance, Neoplasm | 18 | 2022 | 5172 | 0.640 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2018 | 65 | 0.640 |
Why?
|
| Ependymoma | 2 | 2021 | 334 | 0.640 |
Why?
|
| Survival Analysis | 33 | 2023 | 10252 | 0.630 |
Why?
|
| Sural Nerve | 1 | 2018 | 106 | 0.620 |
Why?
|
| Sirolimus | 10 | 2014 | 1564 | 0.620 |
Why?
|
| Dental Caries | 1 | 2021 | 415 | 0.620 |
Why?
|
| Pyridazines | 1 | 2019 | 202 | 0.610 |
Why?
|
| Young Adult | 58 | 2023 | 56430 | 0.610 |
Why?
|
| Angiopoietins | 1 | 2017 | 80 | 0.610 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2012 | 290 | 0.600 |
Why?
|
| Immunotherapy | 21 | 2023 | 4445 | 0.560 |
Why?
|
| Piperidines | 4 | 2015 | 1602 | 0.560 |
Why?
|
| Epothilones | 2 | 2015 | 44 | 0.550 |
Why?
|
| Lung Neoplasms | 18 | 2023 | 13102 | 0.550 |
Why?
|
| Practice Guidelines as Topic | 9 | 2021 | 7279 | 0.550 |
Why?
|
| Decision Making | 5 | 2023 | 3887 | 0.540 |
Why?
|
| Receptors, CXCR4 | 2 | 2018 | 726 | 0.540 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2020 | 2109 | 0.540 |
Why?
|
| Kaplan-Meier Estimate | 19 | 2019 | 6538 | 0.530 |
Why?
|
| Randomized Controlled Trials as Topic | 19 | 2023 | 9959 | 0.520 |
Why?
|
| Venous Thrombosis | 3 | 2019 | 1239 | 0.520 |
Why?
|
| Dose-Response Relationship, Drug | 24 | 2020 | 10943 | 0.520 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2020 | 388 | 0.510 |
Why?
|
| Aged, 80 and over | 53 | 2020 | 57776 | 0.510 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 8 | 2020 | 2737 | 0.510 |
Why?
|
| Signal Transduction | 22 | 2019 | 23403 | 0.500 |
Why?
|
| Electric Conductivity | 5 | 2010 | 411 | 0.500 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2010 | 719 | 0.500 |
Why?
|
| Epilepsy | 7 | 2024 | 3310 | 0.500 |
Why?
|
| Cerebellar Neoplasms | 5 | 2024 | 587 | 0.490 |
Why?
|
| Pathology, Molecular | 3 | 2023 | 326 | 0.490 |
Why?
|
| Sick Role | 1 | 2015 | 237 | 0.490 |
Why?
|
| Tissue Distribution | 11 | 2020 | 2327 | 0.490 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2013 | 358 | 0.480 |
Why?
|
| Telomerase | 5 | 2023 | 730 | 0.480 |
Why?
|
| Retrospective Studies | 65 | 2023 | 77449 | 0.480 |
Why?
|
| DNA Methylation | 11 | 2023 | 4286 | 0.480 |
Why?
|
| Tumor Suppressor Proteins | 11 | 2022 | 2849 | 0.470 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2015 | 1770 | 0.470 |
Why?
|
| Karnofsky Performance Status | 5 | 2019 | 173 | 0.470 |
Why?
|
| Medulloblastoma | 4 | 2022 | 683 | 0.460 |
Why?
|
| Venous Thromboembolism | 3 | 2019 | 1671 | 0.460 |
Why?
|
| Sulfonamides | 5 | 2015 | 1938 | 0.460 |
Why?
|
| Nervous System | 3 | 2017 | 554 | 0.450 |
Why?
|
| Ganciclovir | 1 | 2014 | 258 | 0.450 |
Why?
|
| Bayes Theorem | 7 | 2023 | 2309 | 0.450 |
Why?
|
| Pyrimidinones | 5 | 2023 | 371 | 0.450 |
Why?
|
| Drug Administration Schedule | 19 | 2018 | 4933 | 0.450 |
Why?
|
| Quinoxalines | 1 | 2015 | 290 | 0.450 |
Why?
|
| Periodicals as Topic | 2 | 2015 | 1432 | 0.440 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2014 | 1381 | 0.440 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2021 | 281 | 0.440 |
Why?
|
| Follow-Up Studies | 44 | 2022 | 39050 | 0.430 |
Why?
|
| Oximes | 5 | 2022 | 311 | 0.430 |
Why?
|
| Drug Industry | 1 | 2019 | 746 | 0.430 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2020 | 841 | 0.430 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2023 | 5221 | 0.430 |
Why?
|
| Electroencephalography | 7 | 2010 | 6150 | 0.420 |
Why?
|
| Integrins | 3 | 2015 | 846 | 0.410 |
Why?
|
| Neoplasm Staging | 22 | 2018 | 11031 | 0.410 |
Why?
|
| Piperazines | 5 | 2017 | 2488 | 0.400 |
Why?
|
| Thalidomide | 7 | 2011 | 890 | 0.400 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 733 | 0.390 |
Why?
|
| Neoadjuvant Therapy | 4 | 2019 | 2728 | 0.390 |
Why?
|
| Drug Costs | 1 | 2019 | 1105 | 0.380 |
Why?
|
| Drug Design | 2 | 2016 | 1076 | 0.380 |
Why?
|
| Pyridones | 5 | 2023 | 712 | 0.380 |
Why?
|
| Camptothecin | 8 | 2016 | 576 | 0.380 |
Why?
|
| Promoter Regions, Genetic | 15 | 2021 | 5867 | 0.370 |
Why?
|
| Carcinoma, Small Cell | 4 | 2009 | 420 | 0.370 |
Why?
|
| Valproic Acid | 2 | 2021 | 445 | 0.370 |
Why?
|
| Central Nervous System Diseases | 2 | 2012 | 518 | 0.370 |
Why?
|
| Synapses | 1 | 2020 | 1728 | 0.370 |
Why?
|
| Cerebral Hemorrhage | 6 | 2012 | 2647 | 0.370 |
Why?
|
| Attitude to Health | 1 | 2019 | 2052 | 0.360 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2010 | 23 | 0.360 |
Why?
|
| Receptors, Dopamine D5 | 2 | 2020 | 32 | 0.350 |
Why?
|
| Dendritic Cells | 2 | 2019 | 2725 | 0.350 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 845 | 0.350 |
Why?
|
| Drug Therapy | 2 | 2016 | 497 | 0.350 |
Why?
|
| Self Care | 1 | 2015 | 786 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 1 | 5 | 2014 | 658 | 0.340 |
Why?
|
| Scalp | 2 | 2010 | 380 | 0.330 |
Why?
|
| Rhabdoid Tumor | 2 | 2024 | 212 | 0.330 |
Why?
|
| Neoplasms, Second Primary | 4 | 2022 | 1061 | 0.330 |
Why?
|
| Recurrence | 16 | 2020 | 8340 | 0.330 |
Why?
|
| Drug Therapy, Combination | 9 | 2017 | 6489 | 0.320 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 5 | 2023 | 1660 | 0.320 |
Why?
|
| Glutarates | 3 | 2019 | 236 | 0.320 |
Why?
|
| Contrast Media | 9 | 2020 | 5300 | 0.310 |
Why?
|
| Brain Damage, Chronic | 1 | 2009 | 265 | 0.310 |
Why?
|
| Connective Tissue | 1 | 2010 | 420 | 0.310 |
Why?
|
| Benzoquinones | 1 | 2008 | 201 | 0.310 |
Why?
|
| Patient Preference | 1 | 2015 | 890 | 0.310 |
Why?
|
| Gene Expression Profiling | 9 | 2021 | 9438 | 0.310 |
Why?
|
| Drug Evaluation | 2 | 2008 | 647 | 0.300 |
Why?
|
| Quinolones | 4 | 2017 | 367 | 0.300 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 4 | 2019 | 546 | 0.300 |
Why?
|
| Cytomegalovirus Infections | 1 | 2014 | 820 | 0.300 |
Why?
|
| Skull | 2 | 2010 | 813 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 8428 | 0.290 |
Why?
|
| Models, Anatomic | 2 | 2001 | 691 | 0.290 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2019 | 475 | 0.280 |
Why?
|
| Lactams, Macrocyclic | 1 | 2008 | 320 | 0.280 |
Why?
|
| Intestinal Perforation | 1 | 2008 | 253 | 0.280 |
Why?
|
| PTEN Phosphohydrolase | 6 | 2021 | 1142 | 0.280 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3528 | 0.280 |
Why?
|
| Immunoconjugates | 3 | 2024 | 901 | 0.280 |
Why?
|
| Animals | 67 | 2023 | 168757 | 0.280 |
Why?
|
| Publishing | 1 | 2014 | 833 | 0.280 |
Why?
|
| Brain Mapping | 3 | 2014 | 6669 | 0.270 |
Why?
|
| Lymphopenia | 3 | 2022 | 285 | 0.270 |
Why?
|
| Nervous System Diseases | 2 | 2012 | 1622 | 0.270 |
Why?
|
| Phosphotransferases | 1 | 2007 | 308 | 0.270 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 3229 | 0.270 |
Why?
|
| Models, Biological | 9 | 2021 | 9583 | 0.270 |
Why?
|
| Peptides | 2 | 2021 | 4409 | 0.270 |
Why?
|
| Adolescent | 39 | 2022 | 85781 | 0.260 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 434 | 0.260 |
Why?
|
| Paclitaxel | 1 | 2013 | 1708 | 0.260 |
Why?
|
| Anisotropy | 4 | 2010 | 1265 | 0.260 |
Why?
|
| Quality of Life | 12 | 2024 | 12804 | 0.260 |
Why?
|
| Thrombosis | 1 | 2019 | 2968 | 0.260 |
Why?
|
| Antiviral Agents | 2 | 2016 | 2987 | 0.260 |
Why?
|
| Administration, Oral | 11 | 2021 | 3913 | 0.250 |
Why?
|
| Random Allocation | 4 | 2023 | 2429 | 0.250 |
Why?
|
| Melanoma | 6 | 2023 | 5510 | 0.250 |
Why?
|
| Anticoagulants | 5 | 2019 | 4599 | 0.250 |
Why?
|
| Antigens, Neoplasm | 3 | 2019 | 1988 | 0.240 |
Why?
|
| Neoplasm Invasiveness | 3 | 2009 | 3616 | 0.240 |
Why?
|
| Phenylurea Compounds | 3 | 2022 | 528 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 8 | 2022 | 8949 | 0.240 |
Why?
|
| Comparative Genomic Hybridization | 6 | 2016 | 496 | 0.240 |
Why?
|
| Snake Venoms | 2 | 2015 | 39 | 0.230 |
Why?
|
| Receptor, TIE-2 | 3 | 2019 | 178 | 0.230 |
Why?
|
| Cerebrovascular Disorders | 4 | 2015 | 1504 | 0.230 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2018 | 270 | 0.230 |
Why?
|
| Stereotaxic Techniques | 7 | 1998 | 536 | 0.230 |
Why?
|
| Gene Expression | 4 | 2018 | 7799 | 0.230 |
Why?
|
| Tumor Microenvironment | 8 | 2023 | 3586 | 0.230 |
Why?
|
| Cohort Studies | 20 | 2022 | 40561 | 0.230 |
Why?
|
| Drug Delivery Systems | 6 | 2023 | 2219 | 0.230 |
Why?
|
| Thiazoles | 1 | 2010 | 1483 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2019 | 578 | 0.220 |
Why?
|
| Nuclear Proteins | 6 | 2024 | 5853 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2022 | 3597 | 0.220 |
Why?
|
| Gene Targeting | 1 | 2006 | 880 | 0.220 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2017 | 188 | 0.220 |
Why?
|
| Ganglioglioma | 1 | 2022 | 42 | 0.220 |
Why?
|
| Finite Element Analysis | 3 | 2010 | 431 | 0.220 |
Why?
|
| Heart Transplantation | 3 | 2013 | 3110 | 0.220 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2021 | 288 | 0.210 |
Why?
|
| Immunomodulation | 2 | 2017 | 541 | 0.210 |
Why?
|
| Temporal Lobe | 4 | 2019 | 1670 | 0.210 |
Why?
|
| Tuberous Sclerosis | 1 | 2010 | 1029 | 0.210 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2012 | 624 | 0.210 |
Why?
|
| Dentition, Permanent | 1 | 2021 | 21 | 0.210 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2008 | 957 | 0.210 |
Why?
|
| Boronic Acids | 5 | 2011 | 965 | 0.210 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2022 | 65 | 0.210 |
Why?
|
| Observer Variation | 3 | 2019 | 2593 | 0.200 |
Why?
|
| Nitroimidazoles | 2 | 2021 | 106 | 0.200 |
Why?
|
| Spinal Neoplasms | 2 | 2007 | 760 | 0.200 |
Why?
|
| Thromboembolism | 2 | 2002 | 986 | 0.200 |
Why?
|
| Tooth, Deciduous | 1 | 2021 | 74 | 0.200 |
Why?
|
| Cognition Disorders | 4 | 2011 | 4043 | 0.200 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 2020 | 0.200 |
Why?
|
| Child | 27 | 2024 | 77709 | 0.200 |
Why?
|
| DNA, Neoplasm | 5 | 2022 | 1758 | 0.200 |
Why?
|
| Urogenital Neoplasms | 1 | 2003 | 137 | 0.200 |
Why?
|
| Hepatitis B | 1 | 2007 | 695 | 0.200 |
Why?
|
| Histones | 3 | 2023 | 2599 | 0.200 |
Why?
|
| Germinoma | 1 | 2022 | 133 | 0.200 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2023 | 2455 | 0.200 |
Why?
|
| Phosphoramide Mustards | 1 | 2021 | 16 | 0.200 |
Why?
|
| Paraneoplastic Syndromes | 3 | 2003 | 151 | 0.200 |
Why?
|
| Genomics | 7 | 2024 | 5720 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 3 | 2009 | 2765 | 0.190 |
Why?
|
| Rats | 25 | 2021 | 24260 | 0.190 |
Why?
|
| Dexamethasone | 4 | 2022 | 1951 | 0.190 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2008 | 236 | 0.190 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2021 | 187 | 0.190 |
Why?
|
| Algorithms | 9 | 2020 | 13881 | 0.190 |
Why?
|
| Interleukin-12 | 2 | 2022 | 579 | 0.190 |
Why?
|
| Medical Futility | 1 | 2022 | 127 | 0.190 |
Why?
|
| Treatment Failure | 5 | 2017 | 2618 | 0.190 |
Why?
|
| Societies | 1 | 2021 | 104 | 0.190 |
Why?
|
| Quinolines | 2 | 2016 | 732 | 0.190 |
Why?
|
| Pyrazines | 5 | 2011 | 1230 | 0.190 |
Why?
|
| Reproducibility of Results | 7 | 2023 | 19905 | 0.190 |
Why?
|
| alpha-Fetoproteins | 3 | 1998 | 224 | 0.190 |
Why?
|
| Protein Kinases | 2 | 2006 | 1640 | 0.190 |
Why?
|
| Neoplastic Stem Cells | 4 | 2014 | 1376 | 0.180 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 1799 | 0.180 |
Why?
|
| Risk Assessment | 6 | 2018 | 23338 | 0.180 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 2 | 2011 | 137 | 0.180 |
Why?
|
| Procarbazine | 3 | 2015 | 181 | 0.180 |
Why?
|
| Breast Neoplasms | 9 | 2024 | 20822 | 0.180 |
Why?
|
| DNA Helicases | 2 | 2024 | 859 | 0.180 |
Why?
|
| Lymphoma | 3 | 2023 | 1877 | 0.180 |
Why?
|
| Hydrazines | 1 | 2021 | 226 | 0.180 |
Why?
|
| Palliative Care | 2 | 2014 | 3493 | 0.180 |
Why?
|
| Double-Blind Method | 5 | 2023 | 12026 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 3 | 2019 | 552 | 0.180 |
Why?
|
| Idoxuridine | 5 | 1998 | 123 | 0.170 |
Why?
|
| Oncolytic Viruses | 1 | 2023 | 327 | 0.170 |
Why?
|
| Pyrroles | 3 | 2015 | 1146 | 0.170 |
Why?
|
| Cell Size | 1 | 2021 | 643 | 0.170 |
Why?
|
| Esophageal Neoplasms | 1 | 2009 | 1583 | 0.170 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2016 | 903 | 0.170 |
Why?
|
| United States Food and Drug Administration | 4 | 2021 | 1584 | 0.170 |
Why?
|
| Computer Simulation | 6 | 2023 | 6196 | 0.170 |
Why?
|
| Benzamides | 5 | 2019 | 1379 | 0.170 |
Why?
|
| Action Potentials | 1 | 2006 | 1806 | 0.170 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2019 | 67 | 0.170 |
Why?
|
| Biomedical Research | 1 | 2014 | 3309 | 0.170 |
Why?
|
| Dictionaries as Topic | 1 | 2018 | 12 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2016 | 20129 | 0.170 |
Why?
|
| Adjuvants, Immunologic | 2 | 2008 | 1000 | 0.160 |
Why?
|
| Pityriasis Rubra Pilaris | 1 | 2018 | 12 | 0.160 |
Why?
|
| Dermatitis, Exfoliative | 1 | 2018 | 28 | 0.160 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2020 | 178 | 0.160 |
Why?
|
| Radiation Tolerance | 2 | 2013 | 486 | 0.160 |
Why?
|
| Spinal Cord Compression | 4 | 2005 | 235 | 0.160 |
Why?
|
| Cell Line, Tumor | 14 | 2023 | 16689 | 0.160 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 730 | 0.160 |
Why?
|
| Polyradiculoneuropathy | 1 | 1997 | 64 | 0.160 |
Why?
|
| Receptors, AMPA | 1 | 2020 | 331 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2021 | 2948 | 0.160 |
Why?
|
| Herpesvirus 1, Human | 1 | 2023 | 743 | 0.160 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 498 | 0.160 |
Why?
|
| Cell Cycle Proteins | 4 | 2024 | 3462 | 0.160 |
Why?
|
| Time Factors | 18 | 2020 | 40075 | 0.160 |
Why?
|
| Drug Interactions | 6 | 2007 | 1460 | 0.150 |
Why?
|
| Amphetamine | 1 | 2019 | 225 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2018 | 3760 | 0.150 |
Why?
|
| Vincristine | 3 | 2015 | 1039 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 1790 | 0.150 |
Why?
|
| Neutropenia | 2 | 2015 | 895 | 0.150 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2015 | 789 | 0.150 |
Why?
|
| Leukoencephalopathies | 2 | 2012 | 238 | 0.150 |
Why?
|
| Phentermine | 1 | 1997 | 33 | 0.150 |
Why?
|
| Fenfluramine | 1 | 1997 | 59 | 0.150 |
Why?
|
| Transcription Factors | 8 | 2024 | 12208 | 0.150 |
Why?
|
| Incidence | 12 | 2023 | 20947 | 0.150 |
Why?
|
| Benzylamines | 1 | 2018 | 223 | 0.150 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 4149 | 0.150 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2020 | 449 | 0.150 |
Why?
|
| Chromosome Deletion | 2 | 2014 | 1401 | 0.150 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2011 | 692 | 0.150 |
Why?
|
| Evidence-Based Medicine | 4 | 2018 | 3610 | 0.150 |
Why?
|
| Multiple Myeloma | 6 | 2011 | 5181 | 0.150 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2019 | 339 | 0.150 |
Why?
|
| Neurosciences | 1 | 2022 | 348 | 0.150 |
Why?
|
| Heterocyclic Compounds | 1 | 2018 | 249 | 0.150 |
Why?
|
| Laboratories | 1 | 2021 | 463 | 0.150 |
Why?
|
| DNA Mutational Analysis | 5 | 2021 | 4186 | 0.150 |
Why?
|
| Necrosis | 5 | 2018 | 1643 | 0.150 |
Why?
|
| Brachytherapy | 8 | 1998 | 1248 | 0.140 |
Why?
|
| Appetite Depressants | 1 | 1997 | 110 | 0.140 |
Why?
|
| Micro-Electrical-Mechanical Systems | 1 | 2016 | 31 | 0.140 |
Why?
|
| Pituitary Neoplasms | 2 | 2016 | 1345 | 0.140 |
Why?
|
| Societies, Scientific | 1 | 2018 | 220 | 0.140 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2015 | 528 | 0.140 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 501 | 0.140 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1992 | 1475 | 0.140 |
Why?
|
| Metformin | 1 | 2023 | 835 | 0.140 |
Why?
|
| Medical Informatics Applications | 1 | 2018 | 186 | 0.140 |
Why?
|
| Nausea | 2 | 2017 | 673 | 0.140 |
Why?
|
| Proportional Hazards Models | 11 | 2023 | 12354 | 0.140 |
Why?
|
| Sarcoma | 3 | 2022 | 1897 | 0.140 |
Why?
|
| Soft Tissue Injuries | 1 | 2018 | 176 | 0.140 |
Why?
|
| Imidazolines | 1 | 2015 | 18 | 0.140 |
Why?
|
| Neoplasm, Residual | 2 | 2018 | 973 | 0.140 |
Why?
|
| Age Factors | 8 | 2015 | 18370 | 0.140 |
Why?
|
| Immunohistochemistry | 13 | 2018 | 11366 | 0.140 |
Why?
|
| Neurosurgical Procedures | 5 | 2019 | 2002 | 0.140 |
Why?
|
| Cytokines | 5 | 2019 | 7322 | 0.130 |
Why?
|
| Triazoles | 1 | 2021 | 911 | 0.130 |
Why?
|
| Guanine | 2 | 2016 | 274 | 0.130 |
Why?
|
| STAT6 Transcription Factor | 1 | 2016 | 199 | 0.130 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2015 | 424 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2022 | 804 | 0.130 |
Why?
|
| Protein Isoforms | 1 | 2020 | 1730 | 0.130 |
Why?
|
| Lithium | 1 | 2019 | 601 | 0.130 |
Why?
|
| Peroxynitrous Acid | 1 | 2015 | 41 | 0.130 |
Why?
|
| Antidepressive Agents | 1 | 2007 | 2838 | 0.130 |
Why?
|
| Sulfones | 2 | 2022 | 437 | 0.130 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2018 | 478 | 0.130 |
Why?
|
| Leukopenia | 1 | 2015 | 212 | 0.130 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 110 | 0.130 |
Why?
|
| Neoplasm Metastasis | 7 | 2019 | 4851 | 0.130 |
Why?
|
| Postoperative Care | 2 | 2019 | 1486 | 0.130 |
Why?
|
| Osteoblasts | 1 | 2021 | 1166 | 0.130 |
Why?
|
| Lymphoma, B-Cell | 2 | 2013 | 931 | 0.130 |
Why?
|
| Stem Cells | 1 | 2008 | 3567 | 0.130 |
Why?
|
| Awareness | 1 | 2019 | 640 | 0.130 |
Why?
|
| Cryopreservation | 1 | 2020 | 670 | 0.130 |
Why?
|
| Ankle | 1 | 2018 | 327 | 0.130 |
Why?
|
| Pilot Projects | 4 | 2016 | 8324 | 0.130 |
Why?
|
| Thrombocytopenia | 2 | 2015 | 1179 | 0.130 |
Why?
|
| Headache | 2 | 2012 | 1226 | 0.130 |
Why?
|
| Hyperglycemia | 1 | 2023 | 1373 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 990 | 0.130 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2016 | 143 | 0.120 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 1992 | 1366 | 0.120 |
Why?
|
| Xanthomatosis | 1 | 2014 | 32 | 0.120 |
Why?
|
| Supratentorial Neoplasms | 2 | 2010 | 160 | 0.120 |
Why?
|
| Caspase 8 | 1 | 2015 | 195 | 0.120 |
Why?
|
| Single-Cell Analysis | 2 | 2022 | 2183 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2016 | 2503 | 0.120 |
Why?
|
| Mice | 25 | 2023 | 81183 | 0.120 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 418 | 0.120 |
Why?
|
| Growth Inhibitors | 2 | 2006 | 385 | 0.120 |
Why?
|
| Receptors, Somatostatin | 1 | 2014 | 129 | 0.120 |
Why?
|
| Tyrosine | 1 | 2018 | 1461 | 0.120 |
Why?
|
| Myoclonus | 1 | 1994 | 104 | 0.120 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 449 | 0.120 |
Why?
|
| Semantics | 1 | 2017 | 584 | 0.120 |
Why?
|
| Retreatment | 1 | 2015 | 610 | 0.120 |
Why?
|
| Information Dissemination | 2 | 2021 | 1099 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2009 | 547 | 0.120 |
Why?
|
| Osteogenesis | 1 | 2021 | 1299 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2016 | 322 | 0.120 |
Why?
|
| T-Lymphocytes | 6 | 2023 | 10180 | 0.120 |
Why?
|
| Phosphopyruvate Hydratase | 2 | 2015 | 135 | 0.120 |
Why?
|
| Neoplasms, Nerve Tissue | 1 | 2013 | 23 | 0.120 |
Why?
|
| Infertility, Female | 1 | 2020 | 787 | 0.110 |
Why?
|
| Caudate Nucleus | 1 | 2015 | 393 | 0.110 |
Why?
|
| Pancreatic Polypeptide-Secreting Cells | 1 | 2013 | 2 | 0.110 |
Why?
|
| North America | 4 | 2011 | 1249 | 0.110 |
Why?
|
| Lymphocytes | 3 | 1997 | 2617 | 0.110 |
Why?
|
| Cysts | 1 | 2019 | 678 | 0.110 |
Why?
|
| Genotype | 5 | 2017 | 12951 | 0.110 |
Why?
|
| Travel | 1 | 2019 | 788 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2013 | 640 | 0.110 |
Why?
|
| Remission Induction | 4 | 2015 | 2386 | 0.110 |
Why?
|
| Enzyme Activation | 2 | 2019 | 3701 | 0.110 |
Why?
|
| Transplantation, Heterotopic | 1 | 2013 | 175 | 0.110 |
Why?
|
| Radiopharmaceuticals | 2 | 2022 | 2645 | 0.110 |
Why?
|
| Nitriles | 2 | 2014 | 956 | 0.110 |
Why?
|
| Adenocarcinoma | 3 | 2023 | 6364 | 0.110 |
Why?
|
| Ocular Motility Disorders | 1 | 1994 | 135 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2018 | 764 | 0.110 |
Why?
|
| Image Enhancement | 4 | 2018 | 2921 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2015 | 380 | 0.110 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 592 | 0.110 |
Why?
|
| Mice, Nude | 4 | 2019 | 3689 | 0.110 |
Why?
|
| Mesangial Cells | 1 | 2012 | 24 | 0.110 |
Why?
|
| Gene Fusion | 1 | 2016 | 371 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2016 | 538 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2015 | 8301 | 0.110 |
Why?
|
| Minority Groups | 1 | 2020 | 1223 | 0.110 |
Why?
|
| Iodine Radioisotopes | 5 | 1998 | 1032 | 0.110 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2013 | 200 | 0.110 |
Why?
|
| Europe | 1 | 2019 | 3339 | 0.110 |
Why?
|
| Fibronectins | 2 | 2015 | 726 | 0.110 |
Why?
|
| Caspase 3 | 1 | 2015 | 758 | 0.110 |
Why?
|
| Decision Trees | 1 | 2014 | 506 | 0.110 |
Why?
|
| Neuroprotective Agents | 2 | 2019 | 941 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2012 | 367 | 0.100 |
Why?
|
| Cognition | 3 | 2016 | 6770 | 0.100 |
Why?
|
| Constipation | 2 | 2015 | 546 | 0.100 |
Why?
|
| Genetic Vectors | 7 | 1998 | 3420 | 0.100 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2016 | 428 | 0.100 |
Why?
|
| Glutamates | 1 | 2013 | 398 | 0.100 |
Why?
|
| DNA Fragmentation | 1 | 2012 | 242 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2014 | 551 | 0.100 |
Why?
|
| Phenotype | 6 | 2023 | 16365 | 0.100 |
Why?
|
| Prospective Studies | 14 | 2023 | 53288 | 0.100 |
Why?
|
| Ethical Analysis | 1 | 2011 | 42 | 0.100 |
Why?
|
| Enzyme Induction | 3 | 2007 | 475 | 0.100 |
Why?
|
| Drug Eruptions | 3 | 2014 | 297 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 638 | 0.100 |
Why?
|
| Learning Curve | 1 | 2013 | 208 | 0.100 |
Why?
|
| Propionates | 1 | 2012 | 169 | 0.100 |
Why?
|
| SEER Program | 4 | 2021 | 1508 | 0.100 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2011 | 60 | 0.100 |
Why?
|
| Hepatitis B, Chronic | 1 | 2016 | 393 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 5 | 2015 | 6171 | 0.100 |
Why?
|
| Emergencies | 1 | 1998 | 1170 | 0.100 |
Why?
|
| Erythropoietin | 2 | 2014 | 726 | 0.100 |
Why?
|
| Educational Status | 1 | 2019 | 2540 | 0.100 |
Why?
|
| Parietal Lobe | 2 | 2016 | 838 | 0.100 |
Why?
|
| Predictive Value of Tests | 9 | 2020 | 15076 | 0.100 |
Why?
|
| Proteins | 2 | 2014 | 6103 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2001 | 1139 | 0.100 |
Why?
|
| Meningitis | 1 | 1993 | 216 | 0.100 |
Why?
|
| Societies, Medical | 2 | 2023 | 3743 | 0.100 |
Why?
|
| Lamivudine | 2 | 2016 | 342 | 0.100 |
Why?
|
| Adenoviruses, Human | 3 | 1998 | 257 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 783 | 0.100 |
Why?
|
| Acetamides | 1 | 2013 | 249 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 2019 | 1403 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 2 | 2014 | 4462 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 1276 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2008 | 1676 | 0.100 |
Why?
|
| Genetic Testing | 2 | 2014 | 3444 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2016 | 850 | 0.100 |
Why?
|
| Up-Regulation | 4 | 2019 | 4217 | 0.090 |
Why?
|
| Neoplasm Transplantation | 8 | 2016 | 2085 | 0.090 |
Why?
|
| Burkitt Lymphoma | 1 | 1993 | 327 | 0.090 |
Why?
|
| Depsipeptides | 1 | 2011 | 94 | 0.090 |
Why?
|
| Histocompatibility Antigens | 1 | 1992 | 471 | 0.090 |
Why?
|
| Rats, Inbred F344 | 10 | 1998 | 862 | 0.090 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2011 | 54 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 602 | 0.090 |
Why?
|
| Niacinamide | 1 | 2012 | 417 | 0.090 |
Why?
|
| Central Nervous System Stimulants | 1 | 2019 | 1148 | 0.090 |
Why?
|
| Interferon-gamma | 3 | 2019 | 3206 | 0.090 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2019 | 1624 | 0.090 |
Why?
|
| Drug Approval | 2 | 2014 | 742 | 0.090 |
Why?
|
| Drug Synergism | 3 | 2011 | 1792 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2011 | 227 | 0.090 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2011 | 152 | 0.090 |
Why?
|
| Risk Factors | 9 | 2019 | 72290 | 0.090 |
Why?
|
| Keratin-13 | 1 | 2009 | 11 | 0.090 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2010 | 84 | 0.090 |
Why?
|
| Aniline Compounds | 1 | 2014 | 986 | 0.090 |
Why?
|
| Cell Death | 2 | 2015 | 1706 | 0.090 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2009 | 118 | 0.090 |
Why?
|
| Freeze Drying | 1 | 2009 | 98 | 0.090 |
Why?
|
| DNA Copy Number Variations | 2 | 2015 | 1941 | 0.090 |
Why?
|
| Guidelines as Topic | 3 | 2016 | 1405 | 0.090 |
Why?
|
| Biophysical Phenomena | 1 | 2010 | 327 | 0.090 |
Why?
|
| Chromogranin A | 1 | 2009 | 54 | 0.090 |
Why?
|
| Cyclophosphamide | 3 | 2010 | 2242 | 0.090 |
Why?
|
| Synaptophysin | 1 | 2009 | 141 | 0.090 |
Why?
|
| Surgical Flaps | 1 | 2018 | 1640 | 0.090 |
Why?
|
| Models, Animal | 2 | 2013 | 2171 | 0.080 |
Why?
|
| Stochastic Processes | 1 | 2010 | 344 | 0.080 |
Why?
|
| Spinal Cord Diseases | 1 | 1992 | 298 | 0.080 |
Why?
|
| Receptors, LDL | 1 | 2011 | 475 | 0.080 |
Why?
|
| Electronic Health Records | 2 | 2023 | 4468 | 0.080 |
Why?
|
| Hemoglobins | 1 | 2015 | 1534 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 1526 | 0.080 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2009 | 170 | 0.080 |
Why?
|
| Patient Participation | 1 | 2018 | 1457 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2015 | 2649 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1692 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2020 | 3557 | 0.080 |
Why?
|
| Hemangiosarcoma | 1 | 2011 | 239 | 0.080 |
Why?
|
| Atrophy | 1 | 2013 | 1583 | 0.080 |
Why?
|
| Diarrhea | 1 | 2015 | 1348 | 0.080 |
Why?
|
| Endothelial Cells | 3 | 2011 | 3479 | 0.080 |
Why?
|
| Platelet Count | 1 | 2011 | 781 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 2282 | 0.080 |
Why?
|
| Prevalence | 3 | 2021 | 15226 | 0.080 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2008 | 708 | 0.080 |
Why?
|
| Cluster Analysis | 5 | 2019 | 2715 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2016 | 17446 | 0.080 |
Why?
|
| Hematologic Tests | 1 | 2009 | 240 | 0.080 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2012 | 584 | 0.080 |
Why?
|
| Spinal Nerves | 1 | 2008 | 86 | 0.080 |
Why?
|
| Placebos | 2 | 2020 | 1676 | 0.080 |
Why?
|
| Neurofibromatosis 2 | 1 | 2011 | 380 | 0.080 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2008 | 85 | 0.080 |
Why?
|
| Lipogenesis | 1 | 2009 | 212 | 0.080 |
Why?
|
| Vaccines, Subunit | 1 | 2008 | 168 | 0.080 |
Why?
|
| Drug Monitoring | 3 | 2020 | 956 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 1114 | 0.080 |
Why?
|
| Etanidazole | 3 | 1998 | 26 | 0.080 |
Why?
|
| Phthalazines | 1 | 2010 | 363 | 0.080 |
Why?
|
| Depression | 1 | 2007 | 7766 | 0.080 |
Why?
|
| Models, Theoretical | 2 | 2019 | 3589 | 0.080 |
Why?
|
| Cytotoxins | 1 | 2008 | 153 | 0.080 |
Why?
|
| Gene Deletion | 4 | 2012 | 2751 | 0.080 |
Why?
|
| Gelatin | 1 | 2009 | 225 | 0.080 |
Why?
|
| Nitrosourea Compounds | 1 | 2007 | 32 | 0.080 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2008 | 599 | 0.080 |
Why?
|
| Endostatins | 1 | 2008 | 174 | 0.080 |
Why?
|
| Keratins | 1 | 2009 | 515 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 379 | 0.080 |
Why?
|
| Malondialdehyde | 3 | 1995 | 105 | 0.080 |
Why?
|
| Blood Vessels | 1 | 2013 | 1125 | 0.080 |
Why?
|
| Carmustine | 3 | 2014 | 137 | 0.080 |
Why?
|
| Thrombospondins | 1 | 2008 | 197 | 0.080 |
Why?
|
| Diverticulitis | 1 | 2010 | 171 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2015 | 1058 | 0.070 |
Why?
|
| Topotecan | 1 | 2007 | 137 | 0.070 |
Why?
|
| Antineoplastic Protocols | 1 | 2007 | 50 | 0.070 |
Why?
|
| Brain Diseases | 2 | 1994 | 1563 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2015 | 5179 | 0.070 |
Why?
|
| Fatal Outcome | 6 | 2010 | 1850 | 0.070 |
Why?
|
| Benchmarking | 1 | 2014 | 1042 | 0.070 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 1998 | 238 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2021 | 7729 | 0.070 |
Why?
|
| Pyrazoles | 2 | 2008 | 1972 | 0.070 |
Why?
|
| Stathmin | 1 | 2007 | 71 | 0.070 |
Why?
|
| Carbazoles | 1 | 2008 | 226 | 0.070 |
Why?
|
| Disease Models, Animal | 9 | 2016 | 18029 | 0.070 |
Why?
|
| Diagnosis, Differential | 7 | 2014 | 12959 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 10 | 1999 | 6314 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2011 | 2716 | 0.070 |
Why?
|
| Chromosome Aberrations | 2 | 2011 | 1813 | 0.070 |
Why?
|
| Area Under Curve | 5 | 2016 | 1654 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 2015 | 0.070 |
Why?
|
| United States | 8 | 2021 | 69872 | 0.070 |
Why?
|
| Endocrine System Diseases | 1 | 2009 | 248 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2013 | 1442 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 684 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2017 | 3327 | 0.070 |
Why?
|
| Chemokine CCL2 | 2 | 2001 | 617 | 0.070 |
Why?
|
| Internal Medicine | 2 | 2024 | 1009 | 0.070 |
Why?
|
| Cerebral Arteries | 1 | 2008 | 494 | 0.070 |
Why?
|
| Liver | 3 | 2007 | 7474 | 0.070 |
Why?
|
| Farnesyltranstransferase | 1 | 2006 | 76 | 0.070 |
Why?
|
| Ethics, Medical | 1 | 2011 | 792 | 0.070 |
Why?
|
| Antibodies | 1 | 1994 | 2460 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2009 | 530 | 0.070 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 6993 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2023 | 4554 | 0.070 |
Why?
|
| Brain Stem Neoplasms | 1 | 2008 | 204 | 0.070 |
Why?
|
| Pancreas | 1 | 2013 | 1686 | 0.070 |
Why?
|
| Echocardiography | 1 | 2018 | 5102 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 1863 | 0.070 |
Why?
|
| Ricin | 2 | 1997 | 72 | 0.070 |
Why?
|
| Interleukins | 1 | 2010 | 791 | 0.070 |
Why?
|
| Etoposide | 1 | 2007 | 641 | 0.070 |
Why?
|
| Cell Lineage | 1 | 2014 | 2504 | 0.070 |
Why?
|
| Statistics, Nonparametric | 4 | 2016 | 2886 | 0.070 |
Why?
|
| Cartilage | 1 | 2009 | 818 | 0.070 |
Why?
|
| Esophagectomy | 1 | 2009 | 447 | 0.070 |
Why?
|
| Cell Proliferation | 6 | 2023 | 10481 | 0.070 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2005 | 61 | 0.060 |
Why?
|
| Interferons | 1 | 1989 | 706 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 1994 | 1903 | 0.060 |
Why?
|
| Albumins | 2 | 2000 | 569 | 0.060 |
Why?
|
| Fenretinide | 1 | 2004 | 12 | 0.060 |
Why?
|
| Virus Activation | 1 | 2007 | 319 | 0.060 |
Why?
|
| Immunotoxins | 2 | 1997 | 179 | 0.060 |
Why?
|
| Hypertension | 2 | 2015 | 8480 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2014 | 1786 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2016 | 3023 | 0.060 |
Why?
|
| Comorbidity | 1 | 2019 | 10388 | 0.060 |
Why?
|
| Cell Cycle | 2 | 2011 | 2967 | 0.060 |
Why?
|
| Superoxide Dismutase | 3 | 1995 | 597 | 0.060 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 3 | 1994 | 222 | 0.060 |
Why?
|
| Endorphins | 1 | 1984 | 75 | 0.060 |
Why?
|
| beta-Galactosidase | 4 | 1998 | 573 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2017 | 9849 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 3158 | 0.060 |
Why?
|
| Dynorphins | 1 | 1984 | 84 | 0.060 |
Why?
|
| Myocardium | 2 | 2013 | 4776 | 0.060 |
Why?
|
| Growth Substances | 1 | 2006 | 784 | 0.060 |
Why?
|
| Heroin | 1 | 1984 | 117 | 0.060 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2007 | 615 | 0.060 |
Why?
|
| Survivors | 1 | 2014 | 2291 | 0.060 |
Why?
|
| Gene Dosage | 2 | 2020 | 1252 | 0.060 |
Why?
|
| Deglutition Disorders | 1 | 2009 | 605 | 0.060 |
Why?
|
| Radiotherapy Dosage | 5 | 2019 | 2879 | 0.060 |
Why?
|
| Stem Cell Transplantation | 2 | 2009 | 1620 | 0.060 |
Why?
|
| Radiography | 4 | 2011 | 7023 | 0.060 |
Why?
|
| Claudins | 1 | 2024 | 111 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 1995 | 1620 | 0.060 |
Why?
|
| Lymph Node Excision | 1 | 2009 | 1261 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 4386 | 0.060 |
Why?
|
| Organoplatinum Compounds | 2 | 2018 | 408 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2013 | 3870 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 1344 | 0.060 |
Why?
|
| Gene Expression Regulation | 4 | 2019 | 12072 | 0.050 |
Why?
|
| Risk | 2 | 2015 | 9687 | 0.050 |
Why?
|
| Hippocampus | 1 | 1995 | 3675 | 0.050 |
Why?
|
| Lipase | 1 | 2005 | 314 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2000 | 1341 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 2624 | 0.050 |
Why?
|
| Neuroendocrine Tumors | 1 | 2008 | 594 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 1130 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 2916 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 4479 | 0.050 |
Why?
|
| DNA Repair | 1 | 2011 | 2046 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2017 | 6544 | 0.050 |
Why?
|
| Graft vs Host Disease | 2 | 2009 | 2957 | 0.050 |
Why?
|
| Molecular Biology | 3 | 2012 | 596 | 0.050 |
Why?
|
| Pulmonary Embolism | 2 | 2011 | 2376 | 0.050 |
Why?
|
| Skull Neoplasms | 1 | 2003 | 173 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2022 | 105 | 0.050 |
Why?
|
| Oxygen | 1 | 2013 | 4189 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2007 | 847 | 0.050 |
Why?
|
| Platinum Compounds | 1 | 2022 | 96 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5319 | 0.050 |
Why?
|
| Misonidazole | 1 | 2021 | 34 | 0.050 |
Why?
|
| 5'-Nucleotidase | 1 | 2022 | 160 | 0.050 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2022 | 117 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 3022 | 0.050 |
Why?
|
| International Agencies | 2 | 2012 | 240 | 0.050 |
Why?
|
| Adipocytes | 2 | 1998 | 1184 | 0.050 |
Why?
|
| Transfection | 7 | 1997 | 5892 | 0.050 |
Why?
|
| China | 2 | 2019 | 2248 | 0.050 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 1736 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2006 | 921 | 0.050 |
Why?
|
| Echo-Planar Imaging | 2 | 2014 | 659 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 3670 | 0.050 |
Why?
|
| Standard of Care | 2 | 2017 | 564 | 0.050 |
Why?
|
| Evoked Potentials | 1 | 2006 | 1056 | 0.050 |
Why?
|
| Brain Ischemia | 1 | 2015 | 3265 | 0.050 |
Why?
|
| Genome, Human | 2 | 2020 | 4420 | 0.050 |
Why?
|
| Hodgkin Disease | 1 | 2008 | 1415 | 0.050 |
Why?
|
| DNA, Viral | 1 | 2007 | 2225 | 0.050 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2021 | 162 | 0.050 |
Why?
|
| Ribonuclease III | 1 | 2022 | 275 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2021 | 196 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 644 | 0.040 |
Why?
|
| Feedback | 1 | 2023 | 795 | 0.040 |
Why?
|
| Organotechnetium Compounds | 2 | 1997 | 137 | 0.040 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 12261 | 0.040 |
Why?
|
| Propensity Score | 2 | 2017 | 1781 | 0.040 |
Why?
|
| Carcinoma, Giant Cell | 1 | 1999 | 5 | 0.040 |
Why?
|
| Mathematics | 1 | 2000 | 728 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2011 | 3461 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 375 | 0.040 |
Why?
|
| Models, Statistical | 3 | 2023 | 5102 | 0.040 |
Why?
|
| Tissue Engineering | 1 | 2009 | 1880 | 0.040 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 12245 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 1995 | 5708 | 0.040 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1984 | 632 | 0.040 |
Why?
|
| Biomedical Engineering | 1 | 2000 | 296 | 0.040 |
Why?
|
| Cyclic N-Oxides | 2 | 1995 | 78 | 0.040 |
Why?
|
| Partnership Practice | 1 | 2018 | 16 | 0.040 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 1995 | 165 | 0.040 |
Why?
|
| Child, Preschool | 8 | 2019 | 41006 | 0.040 |
Why?
|
| Nitrogen Oxides | 2 | 1995 | 129 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 3 | 2020 | 4803 | 0.040 |
Why?
|
| DNA | 3 | 2023 | 7301 | 0.040 |
Why?
|
| Free Radicals | 2 | 1995 | 237 | 0.040 |
Why?
|
| International Cooperation | 2 | 2018 | 1420 | 0.040 |
Why?
|
| CDC2 Protein Kinase | 1 | 2019 | 220 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2014 | 8554 | 0.040 |
Why?
|
| Epidural Neoplasms | 1 | 1998 | 24 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 3920 | 0.040 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 1998 | 112 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 705 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 15519 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 250 | 0.040 |
Why?
|
| Ecosystem | 1 | 2022 | 474 | 0.040 |
Why?
|
| Epigenomics | 1 | 2023 | 903 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 648 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2002 | 826 | 0.040 |
Why?
|
| Viral Load | 1 | 2007 | 3299 | 0.040 |
Why?
|
| Binding, Competitive | 2 | 2001 | 1157 | 0.040 |
Why?
|
| Bronchopulmonary Sequestration | 1 | 1997 | 42 | 0.040 |
Why?
|
| Neoplasm Seeding | 1 | 2018 | 87 | 0.040 |
Why?
|
| Triazines | 1 | 2019 | 315 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2001 | 2924 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2020 | 802 | 0.040 |
Why?
|
| Amino Acids | 1 | 2024 | 1736 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2015 | 1038 | 0.040 |
Why?
|
| Adenosine | 1 | 2022 | 825 | 0.040 |
Why?
|
| Dehydroepiandrosterone | 1 | 1998 | 252 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2019 | 229 | 0.040 |
Why?
|
| Spin Labels | 2 | 1995 | 332 | 0.040 |
Why?
|
| Telomere | 1 | 2023 | 910 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 801 | 0.040 |
Why?
|
| Automation | 1 | 2019 | 584 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 4838 | 0.040 |
Why?
|
| Platelet Factor 4 | 1 | 1997 | 129 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2020 | 426 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2022 | 1086 | 0.040 |
Why?
|
| Feasibility Studies | 3 | 2019 | 5078 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2B1 | 1 | 1996 | 21 | 0.040 |
Why?
|
| Cities | 1 | 2019 | 513 | 0.040 |
Why?
|
| Deoxycytidine Kinase | 1 | 1996 | 12 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 2924 | 0.040 |
Why?
|
| Protein Binding | 3 | 2018 | 9386 | 0.040 |
Why?
|
| Flucytosine | 1 | 1996 | 32 | 0.040 |
Why?
|
| Nucleoside Deaminases | 1 | 1996 | 58 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1997 | 177 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 2015 | 1462 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2021 | 1842 | 0.030 |
Why?
|
| Base Sequence | 5 | 2007 | 12797 | 0.030 |
Why?
|
| 4-1BB Ligand | 1 | 2016 | 29 | 0.030 |
Why?
|
| Reference Standards | 1 | 2020 | 1025 | 0.030 |
Why?
|
| OX40 Ligand | 1 | 2016 | 51 | 0.030 |
Why?
|
| Defective Viruses | 1 | 1996 | 112 | 0.030 |
Why?
|
| Probability | 1 | 2022 | 2505 | 0.030 |
Why?
|
| Cadherins | 1 | 2001 | 907 | 0.030 |
Why?
|
| Embryo Transfer | 1 | 2020 | 510 | 0.030 |
Why?
|
| Thymidine | 1 | 2016 | 310 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2011 | 3143 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2020 | 1266 | 0.030 |
Why?
|
| Flavonoids | 1 | 1999 | 443 | 0.030 |
Why?
|
| Ectodysplasins | 1 | 2015 | 11 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2009 | 4776 | 0.030 |
Why?
|
| Hospitalization | 1 | 2015 | 10262 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 549 | 0.030 |
Why?
|
| Immediate-Early Proteins | 1 | 1998 | 453 | 0.030 |
Why?
|
| Hepatitis B virus | 2 | 2016 | 513 | 0.030 |
Why?
|
| Sex Factors | 1 | 2009 | 10397 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2020 | 21746 | 0.030 |
Why?
|
| Interferon-beta | 1 | 1997 | 323 | 0.030 |
Why?
|
| Gadolinium | 1 | 2020 | 952 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2001 | 1364 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2005 | 3200 | 0.030 |
Why?
|
| Obesity | 1 | 1997 | 12745 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1995 | 188 | 0.030 |
Why?
|
| Frozen Sections | 1 | 2015 | 155 | 0.030 |
Why?
|
| Transgenes | 1 | 1998 | 1009 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 780 | 0.030 |
Why?
|
| Molecular Sequence Data | 5 | 2007 | 18111 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 2942 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2006 | 1375 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 4262 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 520 | 0.030 |
Why?
|
| Perfusion | 1 | 2019 | 1360 | 0.030 |
Why?
|
| Hyperplasia | 1 | 1997 | 1185 | 0.030 |
Why?
|
| Liver Neoplasms | 2 | 2008 | 4253 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2015 | 241 | 0.030 |
Why?
|
| Prodrugs | 1 | 1996 | 268 | 0.030 |
Why?
|
| K562 Cells | 1 | 2016 | 634 | 0.030 |
Why?
|
| Cytarabine | 1 | 1996 | 692 | 0.030 |
Why?
|
| Disease Management | 2 | 2017 | 2459 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2001 | 3144 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2016 | 868 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2007 | 419 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 643 | 0.030 |
Why?
|
| Membrane Proteins | 3 | 2011 | 7880 | 0.030 |
Why?
|
| RNA | 1 | 2024 | 2749 | 0.030 |
Why?
|
| Data Collection | 1 | 2023 | 3341 | 0.030 |
Why?
|
| Age of Onset | 1 | 2020 | 3271 | 0.030 |
Why?
|
| Entorhinal Cortex | 1 | 2015 | 272 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2006 | 3748 | 0.030 |
Why?
|
| HLA Antigens | 1 | 1999 | 1381 | 0.030 |
Why?
|
| Selection Bias | 1 | 2015 | 371 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2020 | 3588 | 0.030 |
Why?
|
| Postoperative Complications | 3 | 2013 | 15295 | 0.030 |
Why?
|
| Cerebellar Ataxia | 1 | 1994 | 145 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2022 | 2258 | 0.030 |
Why?
|
| Porphyrins | 1 | 2015 | 348 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 1996 | 913 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14722 | 0.030 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2013 | 41 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 1995 | 634 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2018 | 1609 | 0.030 |
Why?
|
| Infusions, Intravenous | 3 | 2005 | 2274 | 0.030 |
Why?
|
| Valine | 1 | 2014 | 413 | 0.030 |
Why?
|
| Angiogenic Proteins | 1 | 2013 | 104 | 0.030 |
Why?
|
| Radionuclide Imaging | 4 | 2001 | 2031 | 0.030 |
Why?
|
| Benzene Derivatives | 1 | 2012 | 54 | 0.030 |
Why?
|
| Drug Combinations | 1 | 1997 | 1959 | 0.030 |
Why?
|
| Rats, Zucker | 2 | 2001 | 128 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 950 | 0.030 |
Why?
|
| Encephalomyelitis | 1 | 1991 | 34 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 1993 | 588 | 0.030 |
Why?
|
| Coronary Artery Disease | 2 | 2001 | 6487 | 0.030 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 13989 | 0.030 |
Why?
|
| Absorbable Implants | 1 | 2014 | 342 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 890 | 0.030 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2015 | 475 | 0.020 |
Why?
|
| Infant | 4 | 2015 | 35136 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2023 | 2872 | 0.020 |
Why?
|
| Cross-Linking Reagents | 1 | 1994 | 694 | 0.020 |
Why?
|
| Hematinics | 1 | 2014 | 281 | 0.020 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1993 | 249 | 0.020 |
Why?
|
| Cell Survival | 2 | 2018 | 5882 | 0.020 |
Why?
|
| Indazoles | 1 | 2013 | 289 | 0.020 |
Why?
|
| Prenylation | 1 | 2011 | 37 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 1993 | 281 | 0.020 |
Why?
|
| Arteriovenous Malformations | 1 | 1994 | 396 | 0.020 |
Why?
|
| Epithelioid Cells | 1 | 2011 | 71 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 2124 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 5256 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2010 | 6386 | 0.020 |
Why?
|
| Proteomics | 1 | 2024 | 3638 | 0.020 |
Why?
|
| Frontal Lobe | 2 | 2014 | 1406 | 0.020 |
Why?
|
| Adenine | 1 | 2016 | 936 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 1504 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2012 | 569 | 0.020 |
Why?
|
| ROC Curve | 1 | 2018 | 3527 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 3647 | 0.020 |
Why?
|
| Vena Cava Filters | 1 | 1993 | 252 | 0.020 |
Why?
|
| Hydroxyurea | 1 | 2011 | 290 | 0.020 |
Why?
|
| Coronary Vessels | 1 | 2001 | 3107 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2011 | 258 | 0.020 |
Why?
|
| Fever | 1 | 2017 | 1616 | 0.020 |
Why?
|
| Inflammation | 1 | 2010 | 10638 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 1993 | 534 | 0.020 |
Why?
|
| Recombinant Proteins | 3 | 2012 | 6622 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 2214 | 0.020 |
Why?
|
| Medical Records | 2 | 2010 | 1413 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2012 | 697 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2009 | 158 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 2540 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 1994 | 1060 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1994 | 2008 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2000 | 2212 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1997 | 2017 | 0.020 |
Why?
|
| Genes, Bacterial | 2 | 1992 | 1079 | 0.020 |
Why?
|
| Immunity | 1 | 2015 | 1012 | 0.020 |
Why?
|
| Stroke | 1 | 2012 | 9981 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2011 | 282 | 0.020 |
Why?
|
| Molecular Imaging | 1 | 2016 | 828 | 0.020 |
Why?
|
| Autonomic Nervous System | 1 | 2014 | 671 | 0.020 |
Why?
|
| Forecasting | 2 | 1999 | 2951 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 693 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2009 | 322 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1788 | 0.020 |
Why?
|
| CpG Islands | 1 | 2013 | 1172 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 110 | 0.020 |
Why?
|
| Insulin | 1 | 2023 | 6580 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 1997 | 1177 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2015 | 1348 | 0.020 |
Why?
|
| HeLa Cells | 2 | 2011 | 3128 | 0.020 |
Why?
|
| Injections | 1 | 1992 | 840 | 0.020 |
Why?
|
| Microcirculation | 1 | 2013 | 1286 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2014 | 1169 | 0.020 |
Why?
|
| Porosity | 1 | 2009 | 362 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2009 | 682 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2015 | 25625 | 0.020 |
Why?
|
| Crystallization | 1 | 2009 | 524 | 0.020 |
Why?
|
| Equipment Design | 1 | 2016 | 3582 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 560 | 0.020 |
Why?
|
| Cell Division | 4 | 1998 | 4568 | 0.020 |
Why?
|
| Adenoviridae | 3 | 1997 | 1099 | 0.020 |
Why?
|
| Cell Movement | 2 | 2008 | 5217 | 0.020 |
Why?
|
| Polyneuropathies | 1 | 2009 | 137 | 0.020 |
Why?
|
| Encephalitis | 1 | 1991 | 423 | 0.020 |
Why?
|
| Carrier Proteins | 2 | 2000 | 5021 | 0.020 |
Why?
|
| Computational Biology | 1 | 2020 | 3521 | 0.020 |
Why?
|
| Blood Volume | 1 | 2009 | 565 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 2016 | 0.020 |
Why?
|
| Rabbits | 2 | 2009 | 4894 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2007 | 115 | 0.020 |
Why?
|
| Anaplasia | 1 | 2007 | 16 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2016 | 19229 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2009 | 5974 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2017 | 2416 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 380 | 0.020 |
Why?
|
| Skin | 2 | 2018 | 4364 | 0.020 |
Why?
|
| Culture Media | 1 | 2009 | 908 | 0.020 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2008 | 212 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 708 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1992 | 689 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 1993 | 1783 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 279 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 1596 | 0.020 |
Why?
|
| DNA-Binding Proteins | 3 | 2000 | 9648 | 0.020 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 1990 | 356 | 0.020 |
Why?
|
| Apoptosis | 2 | 2015 | 9727 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 1538 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 1184 | 0.020 |
Why?
|
| Injections, Intralesional | 2 | 1998 | 276 | 0.020 |
Why?
|
| Surface Properties | 1 | 2009 | 1184 | 0.020 |
Why?
|
| Biopsy | 2 | 1995 | 6756 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1998 | 3617 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 2013 | 1352 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2013 | 1530 | 0.020 |
Why?
|
| Sacrum | 1 | 2008 | 288 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2015 | 2499 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 1999 | 378 | 0.020 |
Why?
|
| Materials Testing | 1 | 2009 | 867 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 2025 | 0.020 |
Why?
|
| ras Proteins | 1 | 2011 | 1060 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1998 | 3703 | 0.020 |
Why?
|
| Insulin-Secreting Cells | 1 | 2013 | 891 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 791 | 0.020 |
Why?
|
| Particle Size | 1 | 2009 | 1642 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 422 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 1655 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 5524 | 0.020 |
Why?
|
| Enkephalin, Leucine-2-Alanine | 1 | 1984 | 9 | 0.020 |
Why?
|
| Enkephalin, Leucine | 1 | 1984 | 16 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2007 | 464 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 4042 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 2046 | 0.020 |
Why?
|
| Binding Sites | 3 | 2000 | 6114 | 0.020 |
Why?
|
| beta-Endorphin | 1 | 1984 | 53 | 0.020 |
Why?
|
| Skin Neoplasms | 2 | 1995 | 5686 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 769 | 0.010 |
Why?
|
| Retroviridae | 2 | 1997 | 914 | 0.010 |
Why?
|
| Protein Transport | 1 | 2009 | 1988 | 0.010 |
Why?
|
| HIV Infections | 1 | 2010 | 16718 | 0.010 |
Why?
|
| Leukocytes | 1 | 1992 | 2043 | 0.010 |
Why?
|
| Vaccination | 1 | 2016 | 3278 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 2008 | 885 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 3508 | 0.010 |
Why?
|
| Plasmids | 3 | 1995 | 2307 | 0.010 |
Why?
|
| Spinal Cord | 2 | 2005 | 1809 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 1 | 2007 | 512 | 0.010 |
Why?
|
| Autoradiography | 2 | 1997 | 745 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 5391 | 0.010 |
Why?
|
| Medicare | 1 | 2021 | 6566 | 0.010 |
Why?
|
| HIV | 1 | 2010 | 1604 | 0.010 |
Why?
|
| DNA Primers | 1 | 2007 | 2892 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2011 | 1580 | 0.010 |
Why?
|
| Cholesterol | 1 | 2011 | 2917 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2005 | 930 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 4584 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2009 | 1809 | 0.010 |
Why?
|
| Monocytes | 1 | 2011 | 2596 | 0.010 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2010 | 1270 | 0.010 |
Why?
|
| Cell Line | 4 | 2001 | 15997 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 2008 | 1598 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 1998 | 4320 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 2000 | 27 | 0.010 |
Why?
|
| Escherichia coli | 2 | 1992 | 4217 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 2007 | 879 | 0.010 |
Why?
|
| Collagen | 1 | 2009 | 2689 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2000 | 94 | 0.010 |
Why?
|
| Genes, p16 | 1 | 2000 | 157 | 0.010 |
Why?
|
| Genes, erbB-1 | 1 | 2000 | 161 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2010 | 6459 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2009 | 2107 | 0.010 |
Why?
|
| High Mobility Group Proteins | 1 | 2000 | 187 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1984 | 1154 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 2437 | 0.010 |
Why?
|
| Epimedium | 1 | 1999 | 2 | 0.010 |
Why?
|
| Neurons | 1 | 2019 | 9338 | 0.010 |
Why?
|
| Erythema Multiforme | 1 | 1999 | 31 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2000 | 286 | 0.010 |
Why?
|
| HMGB1 Protein | 1 | 2000 | 133 | 0.010 |
Why?
|
| Membrane Fluidity | 1 | 1999 | 73 | 0.010 |
Why?
|
| Radiodermatitis | 1 | 1999 | 60 | 0.010 |
Why?
|
| Glycerolphosphate Dehydrogenase | 1 | 1998 | 39 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2007 | 4740 | 0.010 |
Why?
|
| Phenytoin | 1 | 1999 | 197 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2005 | 1151 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 1998 | 140 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 1999 | 167 | 0.010 |
Why?
|
| Bronchial Arteries | 1 | 1997 | 20 | 0.010 |
Why?
|
| Carcinoma, Embryonal | 1 | 1998 | 38 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2000 | 755 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 2958 | 0.010 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 1997 | 57 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 1997 | 142 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 1999 | 6365 | 0.010 |
Why?
|
| Transcription Factor DP1 | 1 | 1997 | 141 | 0.010 |
Why?
|
| Health Surveys | 1 | 2008 | 4037 | 0.010 |
Why?
|
| Inguinal Canal | 1 | 1997 | 69 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 15540 | 0.010 |
Why?
|
| Presenilin-1 | 1 | 2001 | 635 | 0.010 |
Why?
|
| E2F1 Transcription Factor | 1 | 1997 | 190 | 0.010 |
Why?
|
| Retroperitoneal Space | 1 | 1997 | 176 | 0.010 |
Why?
|
| Reoperation | 2 | 1999 | 4201 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 1997 | 277 | 0.010 |
Why?
|
| Blood Glucose | 2 | 2001 | 6256 | 0.010 |
Why?
|
| Genome | 1 | 2005 | 1808 | 0.010 |
Why?
|
| Transcription, Genetic | 3 | 1997 | 7722 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2000 | 1202 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1998 | 1101 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 2988 | 0.010 |
Why?
|
| Transplantation Tolerance | 1 | 2001 | 617 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 1997 | 303 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 1996 | 128 | 0.010 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 1996 | 68 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1992 | 3523 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2001 | 1539 | 0.010 |
Why?
|
| Cytosine Deaminase | 1 | 1996 | 68 | 0.010 |
Why?
|
| Epididymis | 1 | 1997 | 227 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2001 | 1185 | 0.010 |
Why?
|
| Anemia | 1 | 2005 | 1506 | 0.010 |
Why?
|
| beta Catenin | 1 | 2001 | 1059 | 0.010 |
Why?
|
| Paralysis | 1 | 1997 | 247 | 0.010 |
Why?
|
| Altitude | 1 | 1995 | 161 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2001 | 1836 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1996 | 898 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2001 | 1359 | 0.010 |
Why?
|
| Glycosylation | 1 | 1997 | 1126 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1994 | 349 | 0.010 |
Why?
|
| Bronchi | 1 | 1997 | 840 | 0.010 |
Why?
|
| Logistic Models | 2 | 1999 | 13408 | 0.010 |
Why?
|
| Linear Models | 1 | 2004 | 5952 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1998 | 2839 | 0.010 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 1993 | 159 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 25043 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1993 | 203 | 0.010 |
Why?
|
| Cerebellopontine Angle | 1 | 1993 | 55 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1993 | 878 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1993 | 286 | 0.010 |
Why?
|
| Neural Conduction | 1 | 1994 | 440 | 0.010 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 1994 | 265 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1998 | 1607 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 2000 | 1162 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 1994 | 915 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1994 | 906 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1984 | 5097 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 1997 | 1082 | 0.010 |
Why?
|
| Vitamin E | 1 | 1995 | 869 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 4034 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1995 | 1547 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1996 | 1107 | 0.010 |
Why?
|
| Kinetics | 1 | 1998 | 6473 | 0.010 |
Why?
|
| Lipids | 1 | 2001 | 3305 | 0.010 |
Why?
|
| Acute Disease | 2 | 1991 | 7149 | 0.010 |
Why?
|
| Hemiplegia | 1 | 1990 | 135 | 0.010 |
Why?
|
| Genetic Engineering | 1 | 1995 | 951 | 0.010 |
Why?
|
| Particle Accelerators | 1 | 1990 | 173 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1999 | 3748 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1997 | 2382 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2001 | 3690 | 0.010 |
Why?
|
| Electromyography | 1 | 1994 | 1379 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1993 | 1227 | 0.010 |
Why?
|
| Aphasia | 1 | 1990 | 179 | 0.010 |
Why?
|
| Pain Measurement | 1 | 1998 | 3420 | 0.010 |
Why?
|
| Virus Replication | 1 | 1996 | 2534 | 0.000 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1992 | 712 | 0.000 |
Why?
|
| Antioxidants | 1 | 1995 | 1663 | 0.000 |
Why?
|
| Patient Care Team | 1 | 1999 | 2531 | 0.000 |
Why?
|
| Vomiting | 1 | 1990 | 636 | 0.000 |
Why?
|
| Body Weight | 1 | 1997 | 4669 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 2001 | 13033 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1995 | 2455 | 0.000 |
Why?
|
| Alopecia | 1 | 1990 | 382 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 13815 | 0.000 |
Why?
|
| Cerebrovascular Circulation | 1 | 1996 | 2731 | 0.000 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1998 | 2214 | 0.000 |
Why?
|
| Functional Laterality | 1 | 1992 | 2290 | 0.000 |
Why?
|
| Radiology | 1 | 1999 | 2100 | 0.000 |
Why?
|
| Heart | 1 | 1997 | 4467 | 0.000 |
Why?
|
| Antigens, CD | 1 | 1994 | 4026 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1994 | 4560 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1998 | 11483 | 0.000 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1992 | 2408 | 0.000 |
Why?
|
| Carcinoma | 1 | 1990 | 2375 | 0.000 |
Why?
|
| Pregnancy | 1 | 1992 | 29144 | 0.000 |
Why?
|